BOSTON, Oct. 20, 2017 -- Eze Software, a global provider of investment technology, has been recognized for its technology and service contributions to the hedge fund and mutual fund marketplaces. It recently was named “Best EMS” provider in the HFM European Hedge Fund Technology awards and “Best Portfolio Management Software Provider” in the U.S. Hedge Fund Services awards. Eze was also recognized as the top provider of “Best OMS” and “Best Trading Technology Client Services” at the Mutual Fund Service & Technology Awards.
The awards recognize software, IT, and service providers that serve the hedge fund and mutual fund sectors, respectively, that have demonstrated technological innovation and outstanding client service in the last 12 months. Winners are selected by a panel of editors and independent industry judges.
“We are honored to be recognized for our development efforts and continued dedication to client service across the investment management space,” said Jeffrey Shoreman, President & CEO. “We continue to focus our R&D efforts on delivering best-in-class technology to help investment managers optimize their investment workflows, improve efficiency, and generate more operational alpha.”
In the last 12 months, Eze Software has focused on enhancements across Eze Investment Suite, making significant enhancements to the OMS, EMS, Portfolio Accounting and further enhancing their robust integration. Specifically, the company optimized integration between the EMS and OMS in areas such as trading, compliance and locates services, accomplished seamless OMS/Portfolio Accounting integration, and released several solutions across its product suite to help clients handle the best execution, transaction cost analysis, commission management, and trade and transaction reporting requirements of MiFID II.
Eze Software has experienced steady growth, adding 218 new clients in the 12 months ending Sept. 30, 2017, across all major market regions. The number of clients extending their use of Eze Investment Suite across multiple applications grew by 75% to more than 500.
About Eze Software
Eze Software is a global leading provider of investment management software solutions designed to optimize operational and investment alpha throughout the entire investment process. Eze Software provides the platform for growth for the entire investment management community, maximizing efficiencies across order management, trade execution & analytics, portfolio analytics & modeling, compliance & regulatory reporting, commission management, and portfolio & investor accounting. For more than 20 years Boston-based Eze Software has been driving innovation in financial technology. Today, Eze Software partners with more than 2,500 buy- and sell-side institutions in 45 countries from their 15 offices worldwide. For more information, visit www.ezesoft.com.
Contact: Veronica Belitski Eze Software Group +1 212.506.7523 [email protected]


Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Short Interest Rises in Trump Media Stock After $6 Billion Merger Announcement
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Samsung Signals Comeback With HBM4 Chips as AI Market Heats Up
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 



